VERTEX PHARMACEUTICALS INC / MA

VRTX

Quality scores

Data as of Sep 4, 2026

7 / 9

Strong

7/9 — SOLID fundamentals (high quality).

PassROA > 0 — ROA last year = 15.42 %
PassFCF > 0 — FCF last year = 3,193.80 mill.
FailFCF > net income (accrual quality) — FCF 3,193.80 vs. net income 3,953.20 (mill.)
PassRising ROA — ROA 15.42 % vs. prior year -2.38 %

PassLower long-term leverage — total debt (approx.)/assets 0.00 vs. prior 0.01
PassRising current ratio (more liquidity) — Current ratio 2.90 vs. prior 2.69
PassNo dilution (shares do not grow) — Shares 253.99 mill. vs. prior 256.94 mill.

Test 5: no long-term debt breakdown; approximated with total debt / assets.

Z-Score (original)

14.03

Safe zone

Z''-Score (non-manufacturing)

10.75

Safe zone

Ratio	Value
X1 — Working capital / Total assets	0.29
X2 — Retained earnings / Total assets	0.53
X3 — EBIT / Total assets	0.16
X4 — Market cap / Total liabilities	19.89
X4 — Book equity / Total liabilities	2.68
X5 — Sales / Total assets	0.47